V8 Peptides — Engineered Performance
Research Library
Sermorelin History: How GHRH (1-29) Was Discovered
SermorelinHistory

Sermorelin History: How GHRH (1-29) Was Discovered

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How was sermorelin discovered? Sermorelin is the first 29 residues of growth-hormone-releasing hormone. The hormone was isolated and sequenced in 1982 from human pancreatic tumors that had caused acromegaly, after somatostatin was found in 1973. A sequence analysis showed the 1-29 amide matched longer forms in vitro, the human hypothalamic peptide proved identical in 1984, and the receptor was cloned in 1992.

Most sermorelin pages jump from "a GHRH analog" to protocols. The path from a hypothalamic hypothesis to a 29-residue synthetic peptide is better documented than almost any other peptide in this catalog, and each step is a published paper. This article follows that path, with every statement tied to its source, for laboratory research use only; not for human consumption.

Before the hormone: somatostatin and the search

The history of sermorelin starts with an inhibitor. In 1973 a hypothalamic tetradecapeptide was isolated from ovine tissue that, at about 1 nM, inhibited secretion of immunoreactive growth hormone from rat and human material in vitro and was similarly active in rats; its structure was determined and the synthetic copy was biologically active [1]. That peptide was somatostatin. Its discovery showed that the hypothalamus contains a factor that restrains pituitary growth hormone secretion, and it raised the question of whether a stimulatory counterpart exists. The answer, nine years later, came from an unexpected source.

1982: the pancreatic tumor peptides

In 1982 the factor was isolated from human pancreatic tumors that had caused acromegaly. Two groups reported independently. Guillemin and colleagues isolated a peptide with growth-hormone-releasing activity, gave its 44-residue primary structure, and reported that the synthetic replicate had full biological activity in vitro and in vivo and was identical in activity to the factor in hypothalamic extracts [2]. Rivier and colleagues characterized a growth-hormone-releasing factor from a human pancreatic islet tumor in the same period [3], and a sequence analysis by Spiess, Rivier, Thorner and Vale established an N-terminal sequence of 39 residues by Edman degradation, proposed alanine at position 40 as the free-acid C-terminus, and showed that synthetic hpGRF(1-40)-OH is highly potent in stimulating growth hormone secretion from rat anterior pituitary in vitro and in vivo [4].

The two tumor reports and the sequence analysis share a feature that matters for the compound sold today: they relied on synthesis. Once the structure was known, the peptide could be made in quantity, and that is what allowed the biology to be tested properly. A short paper in the Proceedings of the National Academy of Sciences from the Guillemin laboratory showed that the hypothalamic factor, the tumor-derived factor and synthetic replicates gave identical dose-response curves in primary rat pituitary cell cultures, with a median effective concentration of about 15 pM for the tumor-derived peptide, an effect demonstrable within 30 seconds in a perifusion system, and a specific action on growth hormone, with no demonstrable effect on other pituitary hormones. Somatostatin-28 and somatostatin-14 inhibited the response in a noncompetitive manner, and the authors proposed the name "somatocrinin" for the factor [5].

Why the number is 29

The same Spiess paper that gave the tumor sequence also contained the observation that led to sermorelin. The natural product and the synthetic peptides hpGRF(1-40)-OH, hpGRF(1-40)-NH2 and hpGRF(1-29)-NH2 showed equivalent in vitro activities, and the authors concluded that the C-terminal sequence does not appear to contribute significantly to biologic intrinsic activity and potency [4]. Equivalent activity from a peptide a third shorter was a practical gift: fewer coupling steps, higher yield, easier purification. Sermorelin, GHRH (1-29) amide, is that fragment. The product page lists its sequence and formula, and the structural reading of those entries is laid out in the chemistry article on the notation for amino acid sequences.

YearEventSource type
1973Somatostatin isolated and synthesized; inhibits growth hormone release in vitro and in ratsOriginal isolation paper [1]
1982Growth-hormone-releasing factor isolated from a pancreatic tumor; 44-residue structure; synthetic copy fully activeOriginal isolation paper [2]
1982Characterization and sequence analysis of the tumor peptide; 1-29 amide shown to match longer forms in vitroCharacterization papers [3][4]
1982Synthetic replicates shown to release growth hormone from cultured rat pituitary cells with identical dose-responseIn vitro pharmacology [5]
1983Rat hypothalamic GRF purified, 43 residues, 67% homology with the human peptide in the shared regionSpecies comparison [6]
1984Human hypothalamic GRF isolated; sequence identical to the tumor-derived peptideOriginal isolation paper [7]
1986Plasma degradation of GHRH shown to proceed by N-terminal cleavageMetabolism [8]
1992–1993Pituitary GHRH receptor cloned; receptor mutation identified in the "little" mouseMolecular biology [9][10]

The hypothalamic confirmation and species differences

Because the tumor peptide was a human product, the obvious question was whether the hypothalamus makes the same thing. For the rat the answer was a different peptide: Spiess, Rivier and Vale purified a 43-residue polypeptide from rat hypothalamic extracts on the basis of its ability to stimulate growth hormone secretion from cultured rat anterior pituitary cells, and noted that it shows 67% homology with the corresponding N-terminal 43 residues of the human tumor peptide [6]. The sequence is therefore not conserved across species. For the human the answer was yes: Ling and colleagues isolated the factor from human hypothalamic and hypophysial tissue by acid extraction, immunoaffinity chromatography, gel filtration and two reverse-phase HPLC steps, and found a primary structure identical to the tumor peptide, with major homologies (93%, 89% and 86%) to the hypothalamic peptides of the porcine, bovine, caprine and ovine species [7].

That species difference has a consequence for experimental design that persists today. A human-sequence peptide tested in rat pituitary cells is a heterologous system. In rats, a comparison of human tumor GRF-44 and rat hypothalamic GRF showed that the rat peptide caused significantly more growth hormone release under both conditions tested, and that the size of the response depended on the timing of administration relative to the ultradian growth hormone rhythm, an effect traced to endogenous somatostatin [11]. Anyone reading older rat data with human-sequence peptides should keep that potency gap in mind.

Metabolism, the receptor and the genetic proof

Three advances in the following decade rounded out the picture and still frame how sermorelin is discussed.

Metabolism. Frohman and colleagues examined what plasma does to the 44-residue hormone. When GRH(1-44)-NH2 was incubated with human plasma, HPLC showed a half-life of 17 minutes against 63 minutes by radioimmunoassay, because a less hydrophobic but relatively stable and still immunoreactive peptide appeared; sequencing identified it as GRH(3-44)-NH2, with less than 10-3 of the biological activity of the parent, and the data were interpreted as evidence for inactivation by a plasma dipeptidylaminopeptidase [8]. The N-terminal Tyr-Ala pair of sermorelin is the same site. This is the reason later analog work focused on protecting position 2 and on extending the molecule.

The receptor. Mayo cloned a pituitary-specific GHRH receptor in 1992: a cDNA from rat pituitary encoding a seven-transmembrane G protein-coupled receptor homologous to the secretin and vasoactive intestinal peptide receptors, whose human homolog bound GHRH with high affinity and specificity and raised cAMP in transfected kidney 293 cells [9].

The genetic proof. In the "little" mouse, a hypoplastic anterior pituitary phenotype was traced to a single nucleotide change that converts Asp60 to Gly in the growth hormone releasing factor receptor [10]. A receptor defect alone reproduces the phenotype, which established the receptor as indispensable for somatotroph development and function in that species.

LayerKey findingReported in
MetabolismGHRH(1-44) converted in plasma to GHRH(3-44), under 10-3 of parent activityFrohman 1986 [8]
ReceptorSeven-transmembrane receptor related to secretin and VIP receptors; raises cAMP in transfected cellsMayo 1992 [9]
GeneticsAsp60-to-Gly receptor change in the little mouseLin 1993 [10]

The next layer, mechanism, is covered in the library article on the sermorelin research overview, and the broader biology of the axis, including somatostatin and the secretagogue receptor, is reviewed in the 1999 Physiological Reviews article by Müller, Locatelli and Cocchi [12]. A 1986 Endocrine Reviews article by Frohman and Jansson collects the first three years of work after the structure was determined [13].

What the history changes about how to buy and use a research peptide

History is not just background. Three of its lessons translate into bench decisions:

  • Identity is a sequence, not a name. The original papers established identity by Edman sequencing and by comparing natural and synthetic material. A modern certificate does the equivalent with mass spectrometry; see HPLC versus mass spectrometry and how to read a COA.
  • The active core is short. Equivalent in vitro activity of the 1-29 amide with longer forms explains why the compound exists, and is why sequence-level comparisons against CJC-1295 and tesamorelin concentrate on a handful of positions.
  • Handling inherits the metabolism. The enzymology that inactivates the hormone in plasma has a chemical counterpart in the vial: N-terminal cleavage and deamidation are the routes to watch, which is why cold, dry storage as described on the product page and the guidance in storing research peptides matter.

For those comparing analogs and fragments across the GH axis, the library hub at the research library and the shop list the related compounds, including ipamorelin, a growth hormone secretagogue acting through a different receptor, and sermorelin versus ipamorelin.

All material discussed here is supplied for laboratory research use only; not for human consumption, and nothing in this article is a recommendation for any use outside a research setting.

Frequently asked questions

Who discovered growth-hormone-releasing hormone?

Its structure was determined in 1982 from human pancreatic islet tumors that had caused acromegaly, by groups led by Guillemin, and by Rivier, Spiess and Vale. The human hypothalamic peptide was isolated in 1984 and found identical.

Where was the factor first isolated from?

Hypothalamic tissue yields very little of the factor. The cited papers isolated the factor from such tumors; the human hypothalamic peptide was isolated and sequenced two years later and found identical.

What is the relationship between sermorelin and native GHRH?

Sermorelin is the first 29 residues of the 44-residue human hormone with a C-terminal amide. The 1-29 amide had in vitro activity equivalent to longer forms in the original sequence analysis.

Is rat GHRH the same as human GHRH?

No. A 43-residue rat hypothalamic peptide was found to have 67% homology with the matching region of the human sequence, and it was more potent in rat experiments.

When was the GHRH receptor cloned?

In 1992, as a pituitary-specific G protein-coupled receptor related to the secretin and VIP receptors.

What does the little mouse tell us?

A single Asp60-to-Gly change in the receptor reproduces a hypoplastic pituitary phenotype, showing the receptor is essential in that species.

Why is the N-terminus of GHRH important for stability?

Plasma dipeptidylaminopeptidase removes the first two residues; the resulting 3-44 product had less than one-thousandth of the original activity in a published study.

Where can I find a current structural reading of sermorelin?

The V8 library article on sermorelin structure and synthesis walks through the sequence, formula and salt form.

Related reading: Sermorelin In Vitro: Pituitary Cell Assay Models, Sermorelin Mechanism: GHRH Receptor and cAMP Signaling, Sermorelin Half-Life: What Published Studies Measured.

References

  1. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179(4068):77-9. doi:10.1126/science.179.4068.77
  2. Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-7. doi:10.1126/science.6812220
  3. Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982;300(5889):276-8. doi:10.1038/300276a0
  4. Spiess J, Rivier J, Thorner M, Vale W. Sequence analysis of a growth hormone releasing factor from a human pancreatic islet tumor. Biochemistry. 1982;21(24):6037-40. doi:10.1021/bi00267a002
  5. Brazeau P, Ling N, Böhlen P, Esch F, Ying SY, Guillemin R. Growth hormone releasing factor, somatocrinin, releases pituitary growth hormone in vitro. Proc Natl Acad Sci U S A. 1982;79(24):7909-13. doi:10.1073/pnas.79.24.7909
  6. Spiess J, Rivier J, Vale W. Characterization of rat hypothalamic growth hormone-releasing factor. Nature. 1983;303(5917):532-5. doi:10.1038/303532a0
  7. Ling N, Esch F, Böhlen P, Brazeau P, Wehrenberg WB, Guillemin R. Isolation, primary structure, and synthesis of human hypothalamic somatocrinin: growth hormone-releasing factor. Proc Natl Acad Sci U S A. 1984;81(14):4302-6. doi:10.1073/pnas.81.14.4302
  8. Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest. 1986;78(4):906-13. doi:10.1172/JCI112679
  9. Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6(10):1734-44. doi:10.1210/mend.6.10.1333056
  10. Lin SC, Lin CR, Gukovsky I, Lusis AJ, Sawchenko PE, Rosenfeld MG. Molecular basis of the little mouse phenotype and implications for cell type-specific growth. Nature. 1993;364(6434):208-13. doi:10.1038/364208a0
  11. Tannenbaum GS, Ling N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology. 1984;115(5):1952-7. doi:10.1210/endo-115-5-1952
  12. Müller EE, Locatelli V, Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev. 1999;79(2):511-607. doi:10.1152/physrev.1999.79.2.511
  13. Frohman LA, Jansson JO. Growth hormone-releasing hormone. Endocr Rev. 1986;7(3):223-53. doi:10.1210/edrv-7-3-223

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.